Table 3 Disease activity, damage and health-related quality of life in IIM patients with antisynthetase autoantibodies

MYOACT total (0–10) ***

0.9 [0.4–1.7]

1.5 [0.7–2.5]

0.7 [0.3–1.6]

MYOACT muscular (0–10)

0 [0–2]

0 [0–3]

0 [0–1]

Extramuscular activity in MYOACT (0–10) ***

2 [1–4]

4 [2–6]

2 [1–3]

Physician global activity (0–10) ***

2.8 ± 2.3

4.1 ± 2.3

2.4 ± 2.1

Patient global activity (0–10) ***

3.9 ± 2.5

4.9 ± 2.2

3.5 ± 2.5

MMT-8 (0–80) **

76.0 ± 8.4

74.7 ± 10.4

76.5 ± 7.4

Creatine phosphokinase (mg/dl)

90.5 [55–153.5]

97.5 [56–182]

87.0 [55–140]

Health Assessment Questionnaire (0–3) *

0.753 ± 0.722

0.941 ± 0.768

0.681 ± 0.697

Evaluable damage ***

186 (86.1)

42 (72.4)

143 (91.1)

Myositis Damage Index (0–10)

2.7 ± 2.3

2.9 ± 2.4

2.6 ± 2.2

Physician global damage (0–10)

2.9 ± 2.3

2.9 ± 2.3

2.9 ± 2.2

Patient global damage (0–10)

3.9 ± 2.7

4 ± 2.7

3.9 ± 2.7

SF-12 physical domain score (0–100) ***

37.2 ± 12.7

32.8 ± 12.4

38.9 ± 12.5

SF-12 mental domain score (0–100)

45.5 ± 12.9

43.2 ± 13.5

46.4 ± 12.7